(Source: BioLineRX Ltd) TEL AVIV, Israel, April 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions. The product's commercial launch by Omega Pharma is expected by mid-2016. Subject to the terms of the licensing agreement with Omega Pharma, BioLineRx plans to provide updates at a later stage regarding the commercial potential of the product and its contribution to the Company's ongoing business. BL-5010 is a novel product offering an alternative to painful, invasive and expensive skin lesion removal...
↧
